Eiger BioPharmaceuticals' Core ValuesWe are a values-driven company that works to embody Integrity, Passion, Accountabilitity, Creativity, and Teamwork in the pursuit of our mission.
SpotlightFDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection
Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta (HDV) at the European Association for the Study of the Liver Conference – April 22 to 26, 2015
In the NewsEiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr Joanne Quan, M.D., as Chief Medical Officer & Dr Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs
Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection